Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight

NCT07684235 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07684235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07684235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Recruiting
Start date
July 23, 2026
Completion date
March 19, 2028
Enrollment
3,200 (estimated)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight